# A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

> **NCT04144049** · PHASE2 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 176 (actual)

## Conditions studied

- Submental Fat

## Interventions

- **DRUG:** MT921
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04144049
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-10
- **Primary completion:** 2020-03-10
- **Final completion:** 2020-04-23
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2020-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144049, "A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04144049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*